Fresenius SE & Co. KGaA



 


WELCOME TO FRESENIUS SE

Fresenius - the health care group

Fresenius is a global health care group with products and services for dialysis, the hospital and the medical care of patients at home.

The Fresenius Group consists of the following four business segments that are responsible for their own business operations worldwide: Fresenius Medical Care, Fresenius KabiFresenius Helios and Fresenius Vamed.


Latest news

13.11.2014
Fresenius Medical Care Announces Agreement to Acquire Cogent Healthcare

Fresenius Medical Care announced today that Sound Physicians Inc. (Sound) has entered into an agreement to acquire Cogent Healthcare (Cogent) with more than 650 providers, who offer hospitalist and intensivist services to more than 80 hospitals throughout the United States.

>>>
06.11.2014
Fresenius Kabi and Russian partners terminate joint venture agreement

Fresenius Kabi and its partners Sistema JSFC and Zenitco Finance Management LLC have mutually agreed to terminate the joint venture agreement announced in April 2014. The intention was to combine Fresenius Kabi’s Russian and CIS business with the partners’ subsidiary CJSC Binnopharm.

>>>
04.11.2014
Fresenius posts strong Q3 results and confirms 2014 Group outlook

Ulf Mark Schneider, CEO of Fresenius, said: "Fresenius had a strong third quarter with growth accelerating in all four business segments. Emerging markets stood out with double-digit organic sales growth. (...)"

>>>
04.11.2014
Fresenius Medical Care reports strong operating results for the third quarter 2014 and confirms guidance for full year 2014

Rice Powell, chief executive officer of Fresenius Medical Care stated: “The third quarter has confirmed the positive trend from the previous quarter. Growth rates in revenue and earnings again improved and our operating cash flow has reached an all time high for a single quarter. (...)"

>>>
24.10.2014
Fresenius Medical Care successfully places senior notes

Fresenius Medical Care successfully placed U.S. dollar senior unsecured notes in the amount of $500 million due 2020 with a coupon of 4.125% and in the amount of $400 million due 2024 with a coupon of 4.75%.

>>>